BDX Strategy Progress Meets Reimbursement and Cost Risks

Becton, Dickinson shares were down 0.33% at $183.22 on Monday afternoon. Zacks said the medical technology company’s transformation and recent execution support its outlook, but flagged reimbursement uncertainty, economic pressures and competition.

The stock had fallen 5.3% year to date, while the industry gained 2% and the S&P 500 returned 12.7%, according to Zacks. The research firm said earnings beat consensus estimates in each of the past four quarters, by an average of 2.9%.

BD is focusing on its “Compete, Innovate and Deliver” strategy after separating its Biosciences and Diagnostic Solutions business and combining it with Waters. In the second quarter of fiscal 2026, more than 90% of its portfolio posted mid-single-digit growth, and the company had completed $150 million of a $200 million cost-reduction program, Zacks reported.

The company also partnered with Brazilian pharmaceutical firm EMS in July to launch a semaglutide therapy using BD’s Vystra Injection Pen platform. In August, it completed enrollment in a 477-patient clinical trial evaluating Phasix Mesh for preventing incisional hernias.

Risks include inflation, tariffs and supply-chain disruptions, as well as pricing pressure and changes to reimbursement policies, Zacks said. The firm noted that BD’s international business also leaves it exposed to currency fluctuations.

Zacks said its fiscal 2026 earnings estimate for BD was unchanged at $12.59 per share over the prior 30 days. It pegged fourth-quarter revenue at $5.12 billion, down 13% from the year-earlier quarter.